FeesSafety
Pluang+

Xos unveils rapidly deployable Power Hub energy storage at RE+ 2026 for flexible, scalable power solutions.

Market News
20 Oct 2026, 23:30 WIB
GlobeNewsWire
View Source
Bullish
Xos unveils rapidly deployable Power Hub energy storage at RE+ 2026 for flexible, scalable power solutions.

Xos, Inc. announced its participation in RE+ 2026, showcasing its Power Hub line of rapidly deployable energy storage systems ranging from 210 kWh to 3.1 MWh per unit. These units provide flexible, scalable power solutions that can be quickly connected to grids, generators, or solar arrays, addressing delays in grid connections and supporting diverse applications like data centers, industrial sites, and remote operations. The Power Hub is designed and manufactured in the U.S., offering fast deployment without permanent installation, and can be combined for multi-megawatt utility-scale projects. This innovation aims to help customers meet growing power demands without waiting years for traditional grid upgrades.

Xos and its rapidly deployable Power Hub energy storage system provide context for the energy sector's market activity. For readers following energy stocks, here is Pluang's market snapshot as of Oct 21, 2026 03:42 WIB: Among 79 priced US energy stocks, 44 rose and 33 fell. Notable movers include Solaris Energy Infrastructure Inc. (SEI) at USD 63.07 with a 1-day change of -4.09% and a typical hold time of 3 days, Kinder Morgan Inc. (KMI) at USD 34.16 with a 1-day change of +4.08% and Pluang order activity showing 28% sell and 72% buy over a typical hold time of 151 days, and Delek US Holdings Inc. (DK) at USD 77.58 with a 1-day change of +3.33% and a typical hold time of 6 days.

More News

Philippines solar market to hit 23.35 GW by 2032, growing at 27.46% CAGR driven by cheaper costs and corporate demand

Philippines solar market to hit 23.35 GW by 2032, growing at 27.46% CAGR driven by cheaper costs and corporate demand

The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...

Market News
Bullish
32 minutes ago
Equinor shares trade ex-dividend for Q2 2026 with a $0.39 payout starting Nov 13.

Equinor shares trade ex-dividend for Q2 2026 with a $0.39 payout starting Nov 13.

Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...

Company Fundamentals
Neutral
43 minutes ago
China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signs $540M procurement deals, unveils new aviation tech at CIIE

China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...

Bullish
1 hour ago
Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet launches €500M share capital increase with preferential subscription rights to reduce debt.

Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...

Company Fundamentals
Neutral
3 hours ago
PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

PAS-004 shows strong reductions in neurofibroma size with good safety, advancing to Phase 2 trials after FDA clearance.

Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App